# Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Source: https://onco.cc/trials/nct05226871/  
OnCo record `nct05226871` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.

## Summary

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies is a phase 2 interventional study registered as NCT05226871 by Pfizer, with 35 participants enrolled, started 2022-07-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Palbociclib, Cetuximab, Fulvestrant and Letrozole.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05226871
- Phase: 2
- Setting: A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES
- Sponsor: Pfizer
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT05226871: https://clinicaltrials.gov/study/NCT05226871

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct05226871.json